New clinical data from Phase 1 trial of ZW191 to be presented in an oral presentation on April 21 Preclinical data highlight combination potential for ZW191, a folate receptor alpha (FR⍺)-targeting ...
Assessing the pharmacokinetics (PK) of antibody-drug conjugates (ADCs) in both preclinical and clinical settings is crucial for their development. Biotransformation processes can lead to the creation ...
(RTTNews) - Akari Therapeutics, Plc (Nasdaq: AKTX) yesterday announced that it has initiated GMP manufacturing of its lead antibody-drug conjugate (ADC), AKTX-101, marking a pivotal step toward its ...
Antibody-drug conjugates (ADCs) represent the most successful class of active targeting drug-delivery systems, however, despite the increasing number of FDA approvals treatment-related adverse events ...
BOSTON and LONDON, Sept. 17, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing novel payload antibody drug conjugates (ADCs), today ...
Frazier Life Sciences has launched Callio Therapeutics with $187 million in series A funds and a HER2-targeted dual-payload antibody-drug conjugate that’s ready for the clinic. The ADC, and Callio’s ...
NEWCASTLE, England--(BUSINESS WIRE)--Iksuda Therapeutics (Iksuda), the developer of class leading, clinically validated antibody drug conjugates (ADCs) today announces that it will present three ...
Synaffix, a company of Swiss drugmaker Lonza, has entered into a licensing agreement with South Korean biopharmaceutical firm Qurient to develop a dual-payload antibody-drug conjugate (ADC). Synaffix ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results